ÂÜÀòÂÒÂ×

Mr. Rangachari co-founded InCarda (previously Pleiades Cardio-Therapeutics, Inc.,) along with Drs. Patton, Schuler, and Marcus in 2009. He was the first to identify inhaled cardiology drugs for acute cardiac conditions that formed the basis of InCarda. He set up the operations of the company and defined its lead products.

Mr. Rangachari also consults with several biopharmaceutical companies with project management, drug and device development, quality and regulatory operations, outsourcing, and R&D supply chain in leadership operational roles. Previously Mr. Rangachari was the Managing Director of Nektar Therapeutics (India) Pvt. Ltd., a wholly owned subsidiary of Nektar Therapeutics. He held several leadership roles in Nektar including globalizing Nektar’s R&D; defining and implementing a proprietary products R&D strategy; leading the integration of Aerogen Inc., a liquid pulmonary aerosol technology company, and serving as the program and technology management lead for Nektar’s proprietary products.

Prior to Nektar, Mr. Rangachari established and led the global project management function in Genpharm, Inc., a Canadian subsidiary of Merck KGaA’s generic drug division (now Mylan). Before immigrating to Canada, he worked for more than ten years in the Indian pharmaceutical industry at companies such as Ranbaxy Laboratories, Tablets (India) Pvt. Ltd., SOL Pharmaceuticals Ltd., and TTK Pharma Ltd. in a variety of R&D roles. Narsi received his Masters in pharmaceutical technology from Nagpur University, India. His thesis was in the area of controlled release drug development. He received his B. Pharm. from Madras University, Chennai, India.